All In Biotech

Drug Trial Radar · NCT00717236

Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis

A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.

Last checked: Nov 20, 2026Latest source record: Aug 1, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,648 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,648

Actual

Start

Jul 2008

Primary completion

Mar 2010

Study completion Mar 2011

Sponsor

Lead sponsor
UCB PharmaUCB
Sponsor type
Industry
First posted
Jul 17, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase IIIb multicenter study to evaluate the safety and efficacy of certolizumab pegol (CZP) administered to patients with moderate-to-severe rheumatoid arthritis.

Conditions

  • Rheumatoid Arthritis

Interventions

  • Certolizumab pegol (CZP)Drug

    400 mg CZP given as two 200 mg subcutaneous (sc) injections at Weeks 0, 2, and 4, followed by 200 mg CZP given as 1 sc injection on Weeks 6, 8, and 10. At Week 12 subjects enter the open label phase and receive 200 mg of CZP every other week for a minimum 16 additional weeks until CZP is commercially available.

  • PlaceboOther

    Placebo (0.9% saline) given as 2 subcutaneous (sc) injections at Weeks 0, 2, and 4, followed by placebo given as 1 sc injection on Weeks 6, 8, and 10. At Week 12 subjects enter the open label phase and receive 200 mg of CZP every other week for a minimum 16 additional weeks until CZP is commercially available.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. American College of Rheumatology 20% (ACR20) Response at Week 12Time frame: Baseline, Week 12

Locations

181 sites in 7 countries. Site status is shown where the registry gives one.

  • Site not named

    Birmingham, Alabama

  • Site not named

    Montgomery, Alabama

  • Site not named

    Phoenix, Arizona

  • Site not named

    Tucson, Arizona

  • Site not named

    Hot Springs, Arkansas

  • Site not named

    Little Rock, Arkansas

  • Site not named

    Fullerton, California

  • Site not named

    La Jolla, California

  • Site not named

    Los Angeles, California

  • Site not named

    Palm Desert, California

  • Site not named

    Sacramento, California

  • Site not named

    Santa Barbara, California

  • Site not named

    Santa Maria, California

  • Site not named

    Tustin, California

  • Site not named

    Westlake Village, California

  • Site not named

    Whittier, California

  • Site not named

    Denver, Colorado

  • Site not named

    Danbury, Connecticut

  • Site not named

    Trumbull, Connecticut

  • Site not named

    Lewes, Delaware

  • Site not named

    Newark, Delaware

  • Site not named

    Washington D.C., District of Columbia

  • Site not named

    Boca Raton, Florida

  • Site not named

    Delray Beach, Florida

  • Site not named

    Gainesville, Florida

  • Site not named

    Jacksonville, Florida

  • Site not named

    Orlando, Florida

  • Site not named

    South Miami, Florida

  • Site not named

    Tampa, Florida

  • Site not named

    Tavares, Florida

  • Site not named

    Atlanta, Georgia

  • Site not named

    Coeur d'Alene, Idaho

  • Site not named

    Idaho Falls, Idaho

  • Site not named

    Maywood, Illinois

  • Site not named

    Peoria, Illinois

  • Site not named

    Rock Island, Illinois

  • Site not named

    Springfield, Illinois

  • Site not named

    Evansville, Indiana

  • Site not named

    Indianapolis, Indiana

  • Site not named

    Wichita, Kansas

Showing 40 of 181 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.